Phase 3 Readout~month
Phase 3 Topline: A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy With Nivolumab Versus Placebo Af
- Indication
- Melanoma
Other upcoming events for BMY
Phase 3 ReadoutPhase 3 Topline: A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to So
Phase 2 StartPhase 2 Start: A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination With Other
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Saf
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.